NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $1.23 -0.19 (-13.38%) As of 08/27/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Capstone Therapeutics Stock (NASDAQ:CAPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$1.23▼$1.3850-Day Range$1.01▼$1.8852-Week Range$0.96▼$16.18Volume577,088 shsAverage Volume5.49 million shsMarket Capitalization$6.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Read More Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPS Stock News HeadlinesCapstone Therapeutics Corp.'s (NASDAQ:CAPS) Lock-Up Period Will Expire on September 2nd2 hours ago | americanbankingnews.comMichael ParkerJune 18, 2025 | latimes.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Capstone Holding Corp., Secures $1 Million Pangaea Stone Order in Expanding TerritoryJune 17, 2025 | finanznachrichten.dePinecrest, Florida Resident David Buitrago Completes Intensive Capstone Research ProjectJune 16, 2025 | msn.comA capstone projectJune 14, 2025 | yahoo.comCSM Honors 32 Leaders in 2025 Academy CeremonyJune 14, 2025 | msn.comCapstone Holding Corp. (J7W.F)June 12, 2025 | finance.yahoo.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $2.40 at the beginning of 2025. Since then, CAPS stock has decreased by 48.8% and is now trading at $1.23. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp. (NASDAQ:CAPS) announced its quarterly earnings results on Friday, August, 15th. The company reported ($0.13) earnings per share for the quarter. The firm had revenue of $12.85 million for the quarter. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an initial public offering (IPO) on Thursday, March 6th 2025. The company issued 1,250,000 shares at a price of $4.00 per share. When does Capstone Therapeutics' lock-up period expire? Capstone Therapeutics's lock-up period expires on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. After the end of Capstone Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2025Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPS CIK887151 WebN/A Phone(708) 371-0660Fax602-286-5300Employees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.22 Current Ratio0.97 Quick Ratio0.41 Sales & Book Value Annual Sales$44.88 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book0.26Miscellaneous Outstanding Shares5,580,000Free Float3,192,000Market Cap$6.86 million OptionableN/A Beta-0.80 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CAPS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.